Khiron presents its first research study with 1,400 patients

Results of a 12-month observational study presented at the International Pain Conference in Colombia to September 25e, 2021

  • 1st research study of its kind with a large patient base for medical cannabis in Latin America
  • 1,453 patients over a 12-month period, treated in the Khiron Zerenia clinics in Colombia, using Khiron’s CBD and THC oral sublingual medical cannabis oils
  • 80% of patients with a positive clinical response for chronic pain, nausea, insomnia, anxiety, spasticity and depression

TORONTO, October 7, 2021 / PRNewswire / – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated international cannabis leader with core operations in Latin America and Europe, is pleased to announce that the Company has presented the results of its first research study including 1,453 patients from Zerenia clinics belonging to Khiron at 29e International Pain Conference in Barranquilla, Colombia, organized by ACED, the Colombian chapter of the International Association for the Study of Pain (IASP).

The study, titled “Prescribing models and clinical outcomes in a cohort of patients receiving progressive therapy with cannabinoids for medical use in Colombia“, is a longitudinal and retrospective cohort study including 1,453 patients receiving treatment with medical cannabis in clinics belonging to Khiron in Colombia, Zerenia and ILANS.

The scope of the research was to capture measures of patient-reported outcomes (PROMS) and measures of patient-reported experience (PREMS) of the overall efficacy, adherence and side effects of oral formulations. including cannabinoid content for the treatment of different health problems with a variety of patient bases over a twelve month period.

The research protocol has been reviewed and approved by the Institutional Scientific Committee and the Research Ethics Committee of the Universidad del Bosque, in Colombia, one of the region’s leading medical research institutions.

Demographic results indicated that most patients were female (73%) with an average age of 59.3 years, in stark contrast to the results of Project T21, the UK’s first medical cannabis registry supported by Khiron Life Sciences. since its founding in 2019. Patients in the study were primarily diagnosed with chronic non-cancerous pain (77%), followed by nausea and vomiting (8%), insomnia (6%), anxiety ( 5%), spasticity and depression, among others, and up to 68% of patients saw the cost of their medical cannabis prescription covered by Social Security in Colombia. Study results show a positive clinical response reported by patients in over 80% of participants, with only minor side effects associated with treatment.

Management commentary
“Research and scientific data are essential in convincing physicians and policymakers around the world of the benefits of medical cannabis to treat the conditions prevalent in every company and every market we target. After a year of compiling information and going through a very detailed approval process, we are very proud to share the results of this one-of-a-kind clinical study in Latin America with such a large patient base. This is just the start of our ongoing research program. We look forward to sharing the results of this first cohort study with the international medical public through peer-reviewed specialist publications so that physicians around the world can continue to drive prescription growth in a safe and responsible manner, ” commented Allvaro Torres, Chief Executive Officer and Director of the Company.

About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated international medical cannabis company with primary activities in Latin America and Europe. Leveraging wholly owned health clinics and proprietary telemedicine platforms, Khiron combines a patient-centered approach, physician training programs, scientific expertise, product innovation and agricultural infrastructure to foster prescriptions and brand loyalty with patients around the world. The Company has a commercial presence in Colombia, Peru, Germany, United Kingdom and Brazil and is able to start sales in Mexico. The company is headed by the co-founder and CEO, Allvaro Torres, with an experienced and diverse management team and board of directors.

Visit Khiron online at investors.khiron.ca and
Linkedin on https://www.linkedin.com/company/khiron-life-sciences-corp/

Cautionary Notes

Forward-looking statements

This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws. All information contained in this document that is not historical in nature may constitute forward-looking information. Khiron does not undertake to comment on analyzes, expectations or statements made by third parties concerning Khiron, its titles or its financial or operational results (if applicable). Although Khiron believes that the expectations reflected in the forward-looking statements in this press release are reasonable, these forward-looking statements are based on expectations, factors and assumptions regarding future events which may prove to be inaccurate and are subject to numerous risks and uncertainties. , some of which are beyond Khiron’s control, including the risk factors described in Khiron’s annual information form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and is made as of the date hereof. Khiron disclaims any intention and has no obligation or liability, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of TSXV) accepts responsibility for the adequacy or accuracy of this press release.

SOURCE Khiron Life Sciences Corp.

Related links

https://khiron.ca/


Source link

Paul N. Strickland

Leave a Reply

Your email address will not be published. Required fields are marked *